IN2014CN00437A - - Google Patents
Info
- Publication number
- IN2014CN00437A IN2014CN00437A IN437CHN2014A IN2014CN00437A IN 2014CN00437 A IN2014CN00437 A IN 2014CN00437A IN 437CHN2014 A IN437CHN2014 A IN 437CHN2014A IN 2014CN00437 A IN2014CN00437 A IN 2014CN00437A
- Authority
- IN
- India
- Prior art keywords
- polypeptides
- protein constructs
- compositions
- against ige
- encode
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500449P | 2011-06-23 | 2011-06-23 | |
| PCT/EP2012/062250 WO2012175740A1 (fr) | 2011-06-23 | 2012-06-25 | Domaines variables uniques d'immunoglobuline dirigés contre ige |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00437A true IN2014CN00437A (fr) | 2015-04-03 |
Family
ID=46458485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN437CHN2014 IN2014CN00437A (fr) | 2011-06-23 | 2012-06-25 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2723772A1 (fr) |
| JP (1) | JP2014525736A (fr) |
| CN (1) | CN104271598A (fr) |
| AU (1) | AU2012273928A1 (fr) |
| IN (1) | IN2014CN00437A (fr) |
| WO (1) | WO2012175740A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014087010A1 (fr) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | Polypeptides améliorés dirigés contre ige |
| CN105085677B (zh) * | 2014-05-05 | 2019-01-18 | 中国科学院上海药物研究所 | 抗vegfr2人源纳米抗体ntv1及其制备方法和用途 |
| PT3143042T (pt) | 2014-05-16 | 2020-09-01 | Ablynx Nv | Domínios variáveis de imunoglobulina |
| SG11201811280QA (en) * | 2016-06-23 | 2019-01-30 | Ablynx Nv | Improved pharmacokinetic assays for immunoglobulin single variable domains |
| KR102616835B1 (ko) * | 2016-12-07 | 2023-12-22 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 |
| CN111164104A (zh) | 2017-08-09 | 2020-05-15 | 麻省理工学院 | 白蛋白结合肽缀合物及其方法 |
| JP7266611B2 (ja) * | 2018-02-26 | 2023-04-28 | アブリンクス・エヌ・フェー | ペプチドリンカーをコードする改良されたヌクレオチド配列 |
| CN108535493B (zh) * | 2018-04-10 | 2020-11-03 | 北京康亿鸿科技发展有限公司 | 特异性过敏原IgE的检测方法 |
| GB201818460D0 (en) * | 2018-11-13 | 2018-12-26 | Crescendo Biologics Ltd | Single domain antibodies that bind human serum albumin |
| CN110716054A (zh) * | 2019-09-11 | 2020-01-21 | 天津医科大学 | 一种血清亲细胞性免疫球蛋白e的定量检测试剂盒 |
| CN111875706B (zh) * | 2020-07-16 | 2021-03-30 | 广州康盛生物科技股份有限公司 | 一种抗人IgE蛋白的单域抗体及其应用 |
| IL318098A (en) | 2022-07-01 | 2025-02-01 | Alk Abell? As | IGE-FCER pushers |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| CN120712282A (zh) | 2023-02-17 | 2025-09-26 | 阿布林克斯有限公司 | 结合新生儿fc受体的多肽 |
| CN116640209B (zh) * | 2023-04-06 | 2025-04-15 | 生物岛实验室 | Rab11蛋白的特异性抗体及其制备方法与应用 |
| CN116754773B (zh) * | 2023-05-15 | 2024-06-07 | 江南大学 | 一种免疫球蛋白e的检测试剂盒 |
| CN121335921A (zh) * | 2023-06-29 | 2026-01-13 | 苏州康宁杰瑞生物科技有限公司 | 免疫球蛋白Fc区结合蛋白 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB335768A (en) | 1929-10-24 | 1930-10-02 | Jacoviac Maurice | Improvements in protecting devices for gramophone disc records |
| EP0368684B2 (fr) | 1988-11-11 | 2004-09-29 | Medical Research Council | Clonage de séquences d'immunoglobulines de domaines variables. |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| PT651805E (pt) | 1992-07-17 | 2007-02-28 | Dana Farber Cancer Inst Inc | Método de ligação intracelular de moléculas-alvo |
| PT1589107E (pt) | 1992-08-21 | 2010-03-29 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
| WO1994025591A1 (fr) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION D'ANTICORPS OU DE FRAGMENTS FONCTIONNALISES D'ANTICORPS, DERIVES DES IMMUNOGLOBULINES A CHAINE LOURDE DE $i(CAMELIDAE) |
| ES2155854T3 (es) | 1993-06-09 | 2001-06-01 | Unilever Nv | Procedimiento de produccion de proteinas de fusion que comprende fragmentos de scfv con la ayuda de un molde transformado. |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| CA2183667A1 (fr) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Systeme de liberation d'acide nucleique, son procede de synthese et ses utilisations |
| EP0739981A1 (fr) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire |
| CA2258518C (fr) | 1996-06-27 | 2011-11-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Molecules de reconnaissance ayant une interaction specifique avec le site actif ou la fissure d'une molecule cible |
| AU7298398A (en) | 1996-11-19 | 1998-06-10 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| BR9907241A (pt) | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
| WO1999042077A2 (fr) | 1998-02-19 | 1999-08-26 | Xcyte Therapies, Inc. | Compositions et procedes de regulation de l'activation des lymphocytes |
| EP0967284A1 (fr) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiestérases |
| GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
| AU3041100A (en) | 1999-01-05 | 2000-07-24 | Unilever Plc | Binding of antibody fragments to solid supports |
| ATE276359T1 (de) | 1999-01-19 | 2004-10-15 | Unilever Nv | Verfahren zur herstellung von antikörperfragmenten |
| AU779162B2 (en) | 1999-02-05 | 2005-01-06 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
| ATE364696T1 (de) | 1999-03-15 | 2007-07-15 | Univ British Columbia | Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts |
| OA11862A (en) | 1999-04-22 | 2006-03-02 | Unilever Nv | Inhibition of viral infection using monovalent antigen-binding proteins. |
| IL147022A0 (en) | 1999-06-18 | 2002-08-14 | Cv Therapeutics Inc | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 |
| IL147920A0 (en) | 1999-08-02 | 2002-08-14 | Keygene Nv | Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants |
| GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
| US7358096B1 (en) | 1999-11-29 | 2008-04-15 | Conopco, Inc. | Immobilisation of proteins |
| ES2331051T3 (es) | 1999-11-29 | 2009-12-21 | Bac Ip B.V. | Inmovilizacion de moleculas de union de antigenos de un dominio. |
| DE60041564D1 (de) | 1999-12-24 | 2009-03-26 | Genentech Inc | Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen |
| DE60138333D1 (de) | 2000-03-14 | 2009-05-28 | Unilever Nv | Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen |
| AU2001268855A1 (en) | 2000-05-26 | 2001-12-03 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| WO2002048193A2 (fr) | 2000-12-13 | 2002-06-20 | Unilever N.V. | Réseaux de protéines |
| CA2440582A1 (fr) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Groupes de liaison d'albumine serique |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| WO2003002609A2 (fr) | 2001-06-28 | 2003-01-09 | Domantis Limited | Ligand |
| JP2004538324A (ja) | 2001-08-03 | 2004-12-24 | メディカル リサーチ カウンシル | 細胞内抗体 |
| WO2003025020A1 (fr) | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Procede pour creer une banque d'anticorps de chameaux |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| EP1456410A2 (fr) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes |
| EP1456237A2 (fr) | 2001-12-21 | 2004-09-15 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Procede de clonage de sequences de domaines variables |
| EP1461085A2 (fr) | 2002-01-03 | 2004-09-29 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Immunoconjugues utiles pour le traitement de tumeurs |
| EP1600459A3 (fr) | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
| BRPI0315666B8 (pt) | 2002-10-23 | 2021-05-25 | Ludwig Inst For Cancer Res Ltd | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos |
| EP1558645B1 (fr) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Anticorps a domaine unique stabilises dans une composition pharmaceutique pour inhalation |
| EP2301967A3 (fr) | 2002-11-08 | 2011-07-13 | Ablynx N.V. | Anticorps à domaine unique pour administration nasale |
| NZ540771A (en) * | 2003-01-10 | 2009-05-31 | Ablynx Nv | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| AU2003264053A1 (en) | 2003-08-12 | 2005-03-10 | William M. Yarbrough | Treatment for acne vulgaris and method of use |
| AU2003283136A1 (en) | 2003-11-07 | 2005-05-26 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| BRPI0518151A2 (pt) | 2004-10-13 | 2009-06-16 | Ablynx Nv | polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo |
| CA2595682A1 (fr) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Procede de generation de sequences a domaine variable d'anticorps a chaine lourde |
| CA2608770C (fr) | 2005-05-18 | 2017-05-30 | Ablynx Nv | Nanocorps.tm. utilises contre le facteur-alpha de necrose tumorale |
| CA2960105A1 (fr) | 2005-05-20 | 2006-11-23 | Ablynx Nv | Nanobodies (nanocorps) perfectionnes pour traiter des troubles medies par une agregation |
| GB0520644D0 (en) * | 2005-10-11 | 2005-11-16 | Domantis Ltd | Antibody polypeptide library screening and selected antibody polypeptides |
| WO2008020079A1 (fr) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6 |
| CA2663042A1 (fr) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Proteines a demi-vie longue se liant a l'albumine serique |
| EP2086998B1 (fr) | 2006-10-11 | 2011-12-07 | Ablynx N.V. | Sequences d'acides amines se liant a des proteines seriques essentiellement independamment du ph, composes comprenant celles et utilisations correspondantes |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| CN101611056A (zh) | 2006-12-05 | 2009-12-23 | 埃博灵克斯股份有限公司 | 能够结合于血清蛋白的肽 |
| JP2010518839A (ja) | 2007-02-21 | 2010-06-03 | アブリンクス エン．ヴェー． | 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド |
| EP2152747B1 (fr) | 2007-05-24 | 2018-01-03 | Ablynx N.V. | Séquences d'acides aminés dirigées contre rank-l et polypeptides comprenant ces dernières, destinés au traitement de maladies et affections osseuses |
| US8975382B2 (en) | 2007-11-27 | 2015-03-10 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
| WO2009127691A1 (fr) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant |
| US20110243954A1 (en) | 2008-04-17 | 2011-10-06 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| US9193780B2 (en) | 2008-06-05 | 2015-11-24 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
| WO2011095545A1 (fr) | 2010-02-05 | 2011-08-11 | Ablynx Nv | Peptides capables de se lier à la sérumalbumine, et composés, constructions, et polypeptides comprenant de tels peptides |
-
2012
- 2012-06-25 JP JP2014516386A patent/JP2014525736A/ja active Pending
- 2012-06-25 AU AU2012273928A patent/AU2012273928A1/en not_active Abandoned
- 2012-06-25 WO PCT/EP2012/062250 patent/WO2012175740A1/fr not_active Ceased
- 2012-06-25 IN IN437CHN2014 patent/IN2014CN00437A/en unknown
- 2012-06-25 EP EP12732607.2A patent/EP2723772A1/fr not_active Withdrawn
- 2012-06-25 CN CN201280040978.XA patent/CN104271598A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012273928A1 (en) | 2014-02-06 |
| EP2723772A1 (fr) | 2014-04-30 |
| WO2012175740A1 (fr) | 2012-12-27 |
| JP2014525736A (ja) | 2014-10-02 |
| CN104271598A (zh) | 2015-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00437A (fr) | ||
| IN2014CN00414A (fr) | ||
| TN2012000518A1 (en) | Serum albumin binding molecules | |
| CL2010001425A1 (es) | Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina. | |
| UA115546C2 (uk) | Синтетичний транзитний пептид хлоропластів та спосіб його одержання | |
| CL2013000566A1 (es) | Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
| CL2014001055A1 (es) | Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso. | |
| IN2014DN03451A (fr) | ||
| WO2013184938A3 (fr) | Polypeptides de fusion comprenant des lieurs polypeptides à domaine mucin | |
| CL2014001054A1 (es) | Proteina de enlace que se une al factor de necrosis tumoral alfa (tnf-alfa); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; su uso para tratar un trastorno asociado a tnf-alfa; y metodo para determinar la presencia de tnf-alfa en una muestra. | |
| MX2013012844A (es) | Secuencias de aminoacidos dirigidas contra il-17a, il-17f y/o il-17a/f y polipeptidos que comprenden las mismas. | |
| EA201290567A1 (ru) | Получение гетерологичных полипептидов в микроводорослях, внеклеточные микроводорослевые тельца, композиции и способы их получения и применения | |
| IN2014DN05756A (fr) | ||
| EA201600338A1 (ru) | Биспецифическая связывающая молекула, связывающаяся с vegf и ang2 | |
| CA2818990A1 (fr) | Proteines de repetition concues se liant a l'albumine serique | |
| MY167125A (en) | Modified proteins and peptides | |
| CL2013001625A1 (es) | Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa. | |
| CL2013000074A1 (es) | Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos. | |
| CL2010001427A1 (es) | Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina. | |
| EP2376647A4 (fr) | Système de mono-chargement pour l'introduction sélective d'acides aminés non natifs dans des protéines à l'aide d'un système de synthèse de protéines in vitro | |
| WO2012091564A3 (fr) | Polypeptide de réticulation induisant l'apoptose | |
| IN2014MN01562A (fr) | ||
| MX355199B (es) | Peptidos sinteticos de transito a cloroplastos derivados de brassica. | |
| MX361434B (es) | Proteínas de fusión npp1. | |
| MX2015000754A (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. |